Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG

Guest: Robert Z. Orlowski, MD, PhD

Guest: Paul G. Richardson, MD

With a steadily growing list of therapeutic agents for the treatment of patients with multiple myeloma (MM), hematologist-oncologists are equipped with more therapeutic options in the frontline and salvage settings than ever before. However, this progress brings new challenges. The increasing number of therapeutic agents, the underlying heterogeneity of the disease, and the diversity of the patient population are all factors that make patient management more complex. To help hematologist-oncologists improve their ability to incorporate the most up-to-date clinical evidence when assessing and treating patients with MM this activity will highlight the latest clinical and scientific data on MM presented at the American Society of Hematology 2015 Annual Meeting. Furthermore, the activity will provide learners with expert faculty insights and analysis of the clinical implications of these data on treating and managing patients with MM. FacultyPaul G. Richardson, MD—Program ChairR. J. Corman Professor of MedicineHarvard Medical SchoolClinical Program Leader and DirectorJerome Lipper Multiple Myeloma CenterDana-Farber Cancer InstituteBoston, Massachusetts Robert Z. Orlowski, MD, PhDChairman, Ad InterimDirector of MyelomaDepartment of Lymphoma/MyelomaProfessor, Experimental TherapeuticsDivision of Cancer MedicineUniversity of Texas MD Anderson Cancer CenterHouston, Texas